Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hyperlipoproteinemias

Free Subscription Articles published in Atherosclerosis Retrieve available abstracts of 77 articles: HTML format

Single Articles

September 2025
1. YANG X, Alexander VJ, Xia S, Tsimikas S, et al
   Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndrome.
   Atherosclerosis. 2025;408:120462.
   PubMed     Abstract available
   
   
   
2. MIJNSTER RJM, Mulder JWCM, Galema-Boers AMH, Mattace-Raso F, et al
   Efficacy and safety of PCSK9 monoclonal antibodies in older patients: A real-world registry.
   Atherosclerosis. 2025;408:120229.
   PubMed     Abstract available
   
   
   July 2025
3. CASTRO CABEZAS M, Klop B
   The "SMART" side of hypertriglyceridemia.
   Atherosclerosis. 2025 Jul 25:120467. doi: 10.1016/j.atherosclerosis.2025.120467.
   PubMed    
   
   
   
4. TOFT-NIELSEN F, Emanuelsson F, Nordestgaard BG, Benn M, et al
   Clinical familial hypercholesterolemia, heart healthy dietary adherence, and cardiovascular risk.
   Atherosclerosis. 2025 Jul 24:120463. doi: 10.1016/j.atherosclerosis.2025.120463.
   PubMed     Abstract available
   
   
   
5. KAYIKCIOGLU M
   Making the invisible visible: Leveraging electronic health records to uncover familial hypercholesterolemia in primary care.
   Atherosclerosis. 2025 Jul 22:120454. doi: 10.1016/j.atherosclerosis.2025.120454.
   PubMed    
   
   
   
6. WANG H, Shen C, Yang Y, Li X, et al
   Pigment epithelium-derived factor prevents endothelial dysfunction in early stage of hyperlipidemia by regulating endothelial fatty acid transport.
   Atherosclerosis. 2025;408:120446.
   PubMed     Abstract available
   
   
   
7. SVENDSEN K, Christensen JJ, Igland J, Krogh HW, et al
   Risk of adverse pregnancy outcomes and impact of statin use in pregnant women with familial hypercholesterolemia.
   Atherosclerosis. 2025;408:120442.
   PubMed     Abstract available
   
   
   
8. AKYEA RK, Qureshi N
   Uncovering familial hypercholesterolaemia phenotype in the community: How primary care can transform early detection and management.
   Atherosclerosis. 2025 Jul 9:120427. doi: 10.1016/j.atherosclerosis.2025.120427.
   PubMed    
   
   
   
9. TADA H, Furukawa A, Kojima N, Usui S, et al
   Protein-truncating variants of the cholesteryl ester transfer protein gene and risk for coronary artery disease among patients with heterozygous familial hypercholesterolemia.
   Atherosclerosis. 2025;408:120417.
   PubMed     Abstract available
   
   
   June 2025
10. SHAO C, Zhang S, Cheng Z, Yang K, et al
    Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.
    Atherosclerosis. 2025;407:120408.
    PubMed     Abstract available
    
    
    
11. SCHUITEMA PCE, Visseren FLJ, Nordestgaard BG, Teraa M, et al
    Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease.
    Atherosclerosis. 2025 Jun 14:120411. doi: 10.1016/j.atherosclerosis.2025.120411.
    PubMed     Abstract available
    
    
    
12. GIJON-CONDE T, Banegas JR, Sanchez CF, Alonso R, et al
    Clinical profile of familial hypercholesterolemia phenotype in adults attended in primary care in a large healthcare area.
    Atherosclerosis. 2025 Jun 4:120400. doi: 10.1016/j.atherosclerosis.2025.120400.
    PubMed     Abstract available
    
    
    May 2025
13. NIGMANN C, Neyer M, Draxler-Dworzak S, Baumgartner-Kaut M, et al
    Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C.
    Atherosclerosis. 2025;406:119234.
    PubMed     Abstract available
    
    
    
14. KHOLAIF N, Batha L, Aljenedil S, Awan ZA, et al
    Homozygous familial hypercholesterolemia evaluation and survival single center study in Saudi Arabia: The HESSA registry.
    Atherosclerosis. 2025;405:119214.
    PubMed     Abstract available
    
    
    
15. VAHDAT-LASEMI F, Farhoudi L, Hosseinikhah SM, Santos RD, et al
    Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia.
    Atherosclerosis. 2025;405:119235.
    PubMed     Abstract available
    
    
    April 2025
16. SANTOS RD, Ray KK, De Bacquer D, Jennings C, et al
    Frequency of residual combined dyslipidemia and hypertriglyceridemia in patients with coronary heart disease in 13 countries across 6 WHO Regions: Results from INTERASPIRE.
    Atherosclerosis. 2025;405:119215.
    PubMed     Abstract available
    
    
    
17. BASHIR B, Pasha R, Kamath A, Malik RA, et al
    Small nerve fibre damage and cardiac autonomic dysfunction in patients with hypertriglyceridaemia.
    Atherosclerosis. 2025;405:119186.
    PubMed     Abstract available
    
    
    
18. TADA H, Nohara A, Usui S, Sakata K, et al
    Impact of the clinical diagnostic strata of familial hypercholesterolemia on risk stratification among patients with hypercholesterolemia.
    Atherosclerosis. 2025;404:119185.
    PubMed     Abstract available
    
    
    
19. MULDER JWCM, Schonck WAM, Tromp TR, Reijman MD, et al
    Real-world family planning and pregnancy practices in women with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2025;404:119187.
    PubMed     Abstract available
    
    
    
20. BRINTON EA, Eckel RH, Gaudet D, Ballantyne CM, et al
    Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA.
    Atherosclerosis. 2025;403:119114.
    PubMed     Abstract available
    
    
    March 2025
21. STONEHOUSE W, Benassi-Evans B, Louise J
    The effects of a novel nutraceutical combination on low-density lipoprotein cholesterol and other markers of cardiometabolic health in adults with hypercholesterolaemia: A randomised double-blind placebo-controlled trial.
    Atherosclerosis. 2025;403:119177.
    PubMed     Abstract available
    
    
    
22. MICHIKURA M, Ogura M, Hori M, Matsuki K, et al
    Association of Achilles tendon thickness with lipid profile and carotid IMT in patients with familial hypercholesterolemia.
    Atherosclerosis. 2025;403:119173.
    PubMed     Abstract available
    
    
    
23. VAN DEN BOSCH SE, Hutten BA, Revers A, Schrauben EM, et al
    Association between statin adherence and arterial stiffness in young adult patients with familial hypercholesterolemia: A cross-sectional study.
    Atherosclerosis. 2025;404:119175.
    PubMed     Abstract available
    
    
    February 2025
24. DANIELE T, Laura D, Miriam L, Diane B, et al
    The vicious circle of chronic kidney disease and hypertriglyceridemia: What is first, the hen or the egg?
    Atherosclerosis. 2025;403:119146.
    PubMed     Abstract available
    
    
    
25. IYEN B, Qureshi N, Kai J, Capps N, et al
    Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): A retrospective cohort study of individuals with FH in UK primary care and the UK Simon Broome register, linked with national
    Atherosclerosis. 2025;403:119142.
    PubMed     Abstract available
    
    
    
26. AIN Q, Sikonja J, Sadiq F, Shafi S, et al
    Cascade screening of a Pakistani consanguineous familial hypercholesterolemia cohort: Identification of seven new homozygous patients.
    Atherosclerosis. 2025;402:119118.
    PubMed     Abstract available
    
    
    
27. PAVANELLO C, Suppressa P, Castiglione S, Di Costanzo A, et al
    Sex-related differences in response to lomitapide in HoFH: A subanalysis of the Pan-European Lomitapide retrospective observational study.
    Atherosclerosis. 2025;401:119089.
    PubMed     Abstract available
    
    
    January 2025
28. LIN J, Ji Y, Wang G, Ma X, et al
    Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial.
    Atherosclerosis. 2025;403:119120.
    PubMed     Abstract available
    
    
    
29. GROSELJ U, Kafol J, Molk N, Sedej K, et al
    Prevalence, genetic variants, and clinical implications of hypocholesterolemia in children.
    Atherosclerosis. 2025;400:119065.
    PubMed     Abstract available
    
    
    December 2024
30. AZAR Y, Ludwig TE, Le Bon H, Strom TB, et al
    The singular French PCSK9-p.Ser127Arg gain-of-function variant: A significant player in cholesterol levels from a 775-year-old common ancestor.
    Atherosclerosis. 2024;399:118596.
    PubMed     Abstract available
    
    
    
31. HEATON J, Alshami A, Imburgio S, Upadhyaya V, et al
    Comparison of pooled cohort equation and PREVENT risk calculator for statin treatment allocation.
    Atherosclerosis. 2024;399:118626.
    PubMed     Abstract available
    
    
    November 2024
32. SCHETTLER VJJ, Selke N, Jenke S, Zimmermann T, et al
    The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.
    Atherosclerosis. 2024;398:118601.
    PubMed     Abstract available
    
    
    October 2024
33. BENITEZ-AMARO A, Garcia E, La Chica Lhoest MT, Martinez A, et al
    Targeting LDL aggregation decreases atherosclerotic lipid burden in a humanized mouse model of familial hypercholesterolemia: Crucial role of ApoB100 conformational stabilization.
    Atherosclerosis. 2024 Oct 19:118630. doi: 10.1016/j.atherosclerosis.2024.118630.
    PubMed     Abstract available
    
    
    
34. SMITH TKT, Ghorbani P, LeBlond ND, Nunes JRC, et al
    AMPK-mediated regulation of endogenous cholesterol synthesis does not affect atherosclerosis in a murine Pcsk9-AAV model.
    Atherosclerosis. 2024;397:117608.
    PubMed     Abstract available
    
    
    September 2024
35. LLEWELLYN A, Simmonds M, Marshall D, Harden M, et al
    Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials.
    Atherosclerosis. 2024 Sep 28:118598. doi: 10.1016/j.atherosclerosis.2024.118598.
    PubMed     Abstract available
    
    
    
36. BEA AM, Gonzalez-Guerrero A, Cenarro A, Lamiquiz-Moneo I, et al
    Association of HDL cholesterol with all-cause and cardiovascular mortality in primary hypercholesterolemia.
    Atherosclerosis. 2024 Sep 26:118617. doi: 10.1016/j.atherosclerosis.2024.118617.
    PubMed     Abstract available
    
    
    August 2024
37. STOYELL-CONTI FF, Suresh Kumar M, Zigmond ZM, Rojas MG, et al
    Gene inactivation of lysyl oxidase in smooth muscle cells reduces atherosclerosis burden and plaque calcification in hyperlipidemic mice.
    Atherosclerosis. 2024;397:118582.
    PubMed     Abstract available
    
    
    
38. EYRICH TM, Dalila N, Christoffersen M, Tybjaerg-Hansen A, et al
    Polygenic risk of high LDL cholesterol and ischemic heart disease in the general population.
    Atherosclerosis. 2024;397:118574.
    PubMed     Abstract available
    
    
    June 2024
39. TADA H, Takamura M
    Toward personalized medicine in patients with familial hypercholesterolemia.
    Atherosclerosis. 2024 Jun 18:118522. doi: 10.1016/j.atherosclerosis.2024.118522.
    PubMed    
    
    
    
40. IBRAHIM S, Hartgers ML, Reeskamp LF, Zuurbier L, et al
    LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia.
    Atherosclerosis. 2024 Jun 10:117610. doi: 10.1016/j.atherosclerosis.2024.117610.
    PubMed     Abstract available
    
    
    May 2024
41. BERBERICH AJ, Hegele RA
    Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome.
    Atherosclerosis. 2024;392:117528.
    PubMed    
    
    
    April 2024
42. HARADA-SHIBA M
    How can we improve the prognosis of patients with homozygous familial hypercholesterolemia?
    Atherosclerosis. 2024 Apr 16:117551. doi: 10.1016/j.atherosclerosis.2024.117551.
    PubMed    
    
    
    
43. HENDY LE, Spees LP, Tak C, Carpenter DM, et al
    An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
    Atherosclerosis. 2024;393:117541.
    PubMed     Abstract available
    
    
    
44. IBRAHIM S, Nurmohamed NS, Nierman MC, de Goeij JN, et al
    Enhanced identification of familial hypercholesterolemia using central laboratory algorithms.
    Atherosclerosis. 2024;393:117548.
    PubMed     Abstract available
    
    
    
45. BASHIR B, Kwok S, Wierzbicki AS, Jones A, et al
    Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS).
    Atherosclerosis. 2024;391:117476.
    PubMed     Abstract available
    
    
    March 2024
46. REIJMAN MD, Kusters DM, Groothoff JW, Arbeiter K, et al
    Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN.
    Atherosclerosis. 2024;392:117525.
    PubMed     Abstract available
    
    
    
47. ALONSO R, Arroyo-Olivares R, Diaz-Diaz JL, Fuentes-Jimenez F, et al
    Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Atherosclerosis. 2024 Mar 16:117516. doi: 10.1016/j.atherosclerosis.2024.117516.
    PubMed     Abstract available
    
    
    
48. MELNES T, Bogsrud MP, Christensen JJ, Rundblad A, et al
    Gene expression profiling in elderly patients with familial hypercholesterolemia with and without coronary heart disease.
    Atherosclerosis. 2024;392:117507.
    PubMed     Abstract available
    
    
    
49. ESCATE R, Padro T, Perez de Isla L, Fuentes F, et al
    Circulating miR-6821-5p levels and coronary calcification in asymptomatic familial hypercholesterolemia patients.
    Atherosclerosis. 2024;392:117502.
    PubMed     Abstract available
    
    
    
50. SCHLEGEL A
    Diagnostic challenge of an APOB variant of uncertain significance resolved by transheterozygosity with a pathological LDLR variant and clinical response to therapy.
    Atherosclerosis. 2024;390:117460.
    PubMed    
    
    
    February 2024
51. GUAY SP, Paquette M, Taschereau A, Girard L, et al
    Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia.
    Atherosclerosis. 2024 Feb 27:117489. doi: 10.1016/j.atherosclerosis.2024.117489.
    PubMed     Abstract available
    
    
    January 2024
52. RAGGI P, Takyar FM, Gadiyaram V, Zhang C, et al
    Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial.
    Atherosclerosis. 2024;388:117425.
    PubMed     Abstract available
    
    
    December 2023
53. WODAJE T, Mahdi A, Venkateshvaran A, Habel H, et al
    Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2023;389:117439.
    PubMed     Abstract available
    
    
    
54. ANDRADE MM, Neto Goncalves T, Cruz D
    Familial hypercholesterolemia diagnostic challenge: Is Artificial Intelligence the key?
    Atherosclerosis. 2023 Dec 27:117435. doi: 10.1016/j.atherosclerosis.2023.117435.
    PubMed    
    
    
    
55. FISHBEIN I, Inamdar VV, Alferiev IS, Bratinov G, et al
    Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide.
    Atherosclerosis. 2023;390:117432.
    PubMed     Abstract available
    
    
    November 2023
56. MOLOKHIA M, Wierzbicki AS, Williams H, Kirubakaran A, et al
    Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): A cross-sectional database study in Lambeth, South London.
    Atherosclerosis. 2023;388:117353.
    PubMed     Abstract available
    
    
    
57. ZUBIRAN R, Vargas-Vazquez A, Olvera FDR, Cruz-Bautista I, et al
    Performance of the enhanced Sampson-NIH equation for VLDL-C and LDL-C in a population with familial combined hyperlipidemia.
    Atherosclerosis. 2023;386:117364.
    PubMed     Abstract available
    
    
    
58. HOLVEN KB, Roeters van Lennep J
    Sex differences in lipids: A life course approach.
    Atherosclerosis. 2023;384:117270.
    PubMed     Abstract available
    
    
    
59. GOLDBERG AC, Banach M, Catapano AL, Duell PB, et al
    Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
    Atherosclerosis. 2023;384:117192.
    PubMed     Abstract available
    
    
    October 2023
60. KATZMANN JL, Laufs U
    Liver transplantation for homozygous familial hypercholesterolemia: Cure for a genetic disease?
    Atherosclerosis. 2023 Oct 16:117337. doi: 10.1016/j.atherosclerosis.2023.117337.
    PubMed    
    
    
    
61. JUNNA N, Ruotsalainen S, Ripatti P, FinnGen, et al
    Novel Finnish-enriched variants causing severe hypercholesterolemia and their clinical impact on coronary artery disease.
    Atherosclerosis. 2023 Oct 12:117327. doi: 10.1016/j.atherosclerosis.2023.117327.
    PubMed     Abstract available
    
    
    
62. PAGE MM, Hardikar W, Alex G, Bates S, et al
    Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand.
    Atherosclerosis. 2023 Oct 10:117305. doi: 10.1016/j.atherosclerosis.2023.117305.
    PubMed     Abstract available
    
    
    
63. SANTOS RD
    Improving pediatric familial hypercholesterolemia diagnosis by looking deeper into families.
    Atherosclerosis. 2023 Oct 1:117317. doi: 10.1016/j.atherosclerosis.2023.117317.
    PubMed    
    
    
    September 2023
64. ALBUQUERQUE J, Medeiros AM, Alves AC, Jannes CE, et al
    Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adults.
    Atherosclerosis. 2023;383:117314.
    PubMed     Abstract available
    
    
    August 2023
65. CASULA M, Gazzotti M, Capra ME, Olmastroni E, et al
    Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
    Atherosclerosis. 2023 Aug 12:117231. doi: 10.1016/j.atherosclerosis.2023.117231.
    PubMed     Abstract available
    
    
    
66. HON A, Hsu JJ, Zambrano A, Xia Y, et al
    Effects of activity levels on aortic calcification in hyperlipidemic mice as measured by microPETmicroCT.
    Atherosclerosis. 2023;380:117198.
    PubMed     Abstract available
    
    
    
67. SHAPIRO MD, Taub PR, Louie MJ, Lei L, et al
    Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
    Atherosclerosis. 2023;378:117182.
    PubMed     Abstract available
    
    
    
68. MURPHY JM, Jeong K, Tran DTK, Cioffi DL, et al
    Nuclear FAK in endothelium: An intrinsic inhibitor of NF-kappaB activation in atherosclerosis.
    Atherosclerosis. 2023;379:117189.
    PubMed     Abstract available
    
    
    July 2023
69. SIMONEN P, Oorni K, Sinisalo J, Strandberg TE, et al
    High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?
    Atherosclerosis. 2023;376:53-62.
    PubMed     Abstract available
    
    
    June 2023
70. JONES A, Peers K, Wierzbicki AS, Ramachandran R, et al
    Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
    Atherosclerosis. 2023;375:67-74.
    PubMed     Abstract available
    
    
    
71. COSIN-SALES J, Campuzano Ruiz R, Diaz Diaz JL, Escobar Cervantes C, et al
    Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
    Atherosclerosis. 2023;375:38-44.
    PubMed     Abstract available
    
    
    May 2023
72. DOI T, Langsted A, Nordestgaard BG
    Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.
    Atherosclerosis. 2023 May 13:S0021-9150(23)00204.
    PubMed     Abstract available
    
    
    
73. SONMEZ A, Demirci I, Haymana C, Tasci I, et al
    Clinical characteristics of adult and paediatric patients with familial hypercholesterolemia: A real-life cross-sectional study from the Turkish National Database.
    Atherosclerosis. 2023;375:9-20.
    PubMed     Abstract available
    
    
    April 2023
74. RODRIGUEZ-BORJABAD C, Narveud I, Christensen JJ, Ibarretxe D, et al
    Association between Nordic and Mediterranean diets with lipoprotein phenotype assessed by (1)HNMR in children with familial hypercholesterolemia.
    Atherosclerosis. 2023;373:38-45.
    PubMed     Abstract available
    
    
    
75. SCHREUDER MM, Hamkour S, Siegers KE, Holven KB, et al
    LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Atherosclerosis. 2023 Apr 13:S0021-9150(23)00139.
    PubMed     Abstract available
    
    
    
76. HEDEGAARD BS, Bork CS, Kanstrup HL, Thomsen KK, et al
    Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study.
    Atherosclerosis. 2023;373:10-16.
    PubMed     Abstract available
    
    
    March 2023
77. TADA H, Nomura A, Nohara A, Usui S, et al
    Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2023 Mar 17:S0021-9150(23)00103.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hyperlipoproteinemias is free of charge.